Literature DB >> 22337906

An atypical case of familial glucocorticoid deficiency without pigmentation caused by coexistent homozygous mutations in MC2R (T152K) and MC1R (R160W).

Serap Turan1, Claire Hughes, Zeynep Atay, Tulay Guran, Belma Haliloglu, Adrian J L Clark, Abdullah Bereket, Louise A Metherell.   

Abstract

CONTEXT: Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disorder characterized by isolated cortisol deficiency. Mutations in the gene encoding the ACTH receptor (MC2R) account for 25% of cases. One significant feature is generalized skin hyperpigmentation, which is thought to be due to elevated ACTH acting on the melanocortin 1 receptor (MC1R).
OBJECTIVE: The aim of the study was to determine the cause of a nonhyperpigmented case of FGD. PATIENTS: The patient presented at 4 yr of age with hypoglycemia after prolonged fasting during a respiratory tract infection. She had further hypoglycemic attacks and was diagnosed with isolated glucocorticoid deficiency at 6 yr of age. Her parents were consanguineous, and she had two unaffected sisters. Her physical examination was normal, except that her height and weight were greater than the 97th centile for a sex- and age-matched reference population. Interestingly, she had no hyperpigmentation despite very high ACTH levels.
RESULTS: Nucleotide sequence analysis revealed homozygous mutations c.478C>T in MC1R and c.455C>A in MC2R leading to R160W and T152K changes in the amino acid sequences, respectively. The R160W MC1R change has previously been implicated in a red hair/pale skin phenotype, and MC2R -T152K is trafficking defective. Both parents and two unaffected sisters were heterozygous for the MC1R mutation; additionally, one unaffected sister was heterozygous for the MC2R mutation, and the other was wild-type.
CONCLUSION: We report an unusual case of FGD without hyperpigmentation due to coexistent MC1R/MC2R mutations. This case is important because it demonstrates for the first time that the assumption that the action of ACTH on MC1R causes skin hyperpigmentation is correct.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22337906      PMCID: PMC3396854          DOI: 10.1210/jc.2011-2414

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disorder in which cortisol and adrenal androgen secretions are deficient due to adrenal unresponsiveness to ACTH stimulation. The most significant phenotypic features are severe neonatal hypoglycemia, frequent childhood infection, and excessive generalized skin pigmentation related to elevated proopiomelanocortin (POMC) products (1). FGD can be caused by mutations in genes encoding the ACTH receptor [melanocortin 2 receptor (MC2R)] or its accessory protein (MRAP), and a similar clinical presentation has been observed in some patients with specific “mild” mutations in the steroidogenic acute regulatory protein (2–4). Most commonly, MC2R is mutated, and this is referred to as FGD type 1 (OMIM 202200). MSH (melanotropin) and ACTH are products of the same gene, POMC, and they regulate pigmentation and adrenocortical function, respectively (5). Mutations in POMC result in a red hair phenotype with metabolic abnormalities, including adrenal insufficiency and obesity (6). MC1R plays a central role in the regulation of skin pigmentation, is expressed in melanocytes, and binds α-MSH and ACTH with similar affinity. MC1R activation increases the ratio of black, strongly photoprotective eumelanins to reddish, poorly photoprotective pheomelanins (7). Several MC1R variants are associated with red hair/fair skin (7–9). Increased circulating ACTH acting through MC1R is believed to be the cause of the hyperpigmentation seen in primary adrenal failure. There are, however, a few reports of Addison's cases without hyperpigmentation (10–21). So far, no pathogenetic mechanism has been described to explain this phenomenon, although it has been noted that it is more frequently observed in fair-skinned individuals. Here we report coexistent homozygous MC2R and MC1R mutations in the same individual, causing an unusual presentation of FGD without hyperpigmentation.

Patient and Methods

The patient presented at 4 yr of age with hypoglycemia during a respiratory tract infection after prolonged fasting. She had three further hypoglycemic attacks in the following 2 yr during infections. At the age of 6, during evaluation of her fifth hypoglycemic attack, she was diagnosed with hypocortisolemia with elevated ACTH levels. A standard ACTH stimulation test revealed a subnormal response (Table 1). Absence of salt wasting with normal plasma renin activity and without elevation of adrenal glucocorticoid precursors was consistent with isolated glucocorticoid deficiency (Table 1).
Table 1.

Biochemical and hormonal values at baseline and after a standard dose (250 μg) ACTH test

Patient levelsReference ranges
ACTH>1250 pg/ml (275 pmol/liter)b<46 pg/ml (10.1 pmol/liter)b
Cortisol at diagnosis2.56 μg/dl (71.1 nmol/liter)a5–23 μg/dl (139–639 nmol/liter)a
Cortisol in standard dose ACTH stimulation test (250 μg)4.9 μg/dl (136.1 nmol/liter)b5–23 μg/dl (139–639 nmol/liter)b
6.6 μg/dl (183.3 nmol/liter)c>20 μg/dl (>550 nmol/liter)c
DHEAS<15 μg/dl (0.39 μmol/liter)2.3–15 μg/dl (0.06–0.39 μmol/liter)
Na and K136 and 3.14 mEq/liter134–145 and 3.5–5.3 mEq/liter
Aldosterone50 pg/ml (138.8 pmol/liter)10–180 pg/ml (27.7–500 pmol/liter)
Plasma renin activity2.5 ng/ml · h (3.2 pmol/ml · h)1–6.5 ng/ml · h (1.3–8.4 pmol/ml · h)

The patient was found to have hypocortisolemia at the time of hypoglycemia, but ACTH levels were not measured at this time because no hyperpigmentation was present. DHEAS, Dehydroepiandrosterone sulfate. Conversion factors: DHEAS, 1 μg/dl = 38.46 μmol/liter; cortisol, 1 μg/dl = 0.036 nmol/liter; aldosterone, 1 pg/ml = 0.36 pmol/liter; ACTH, 1 pg/ml = 4.54 pmol/liter; plasma renin activity, 1 ng/ml · h = 0.77 pmol/ml · h.

At the time of hypoglycemia (glucose, 25 mg/dl);

before, and

after ACTH stimulation test.

Biochemical and hormonal values at baseline and after a standard dose (250 μg) ACTH test The patient was found to have hypocortisolemia at the time of hypoglycemia, but ACTH levels were not measured at this time because no hyperpigmentation was present. DHEAS, Dehydroepiandrosterone sulfate. Conversion factors: DHEAS, 1 μg/dl = 38.46 μmol/liter; cortisol, 1 μg/dl = 0.036 nmol/liter; aldosterone, 1 pg/ml = 0.36 pmol/liter; ACTH, 1 pg/ml = 4.54 pmol/liter; plasma renin activity, 1 ng/ml · h = 0.77 pmol/ml · h. At the time of hypoglycemia (glucose, 25 mg/dl); before, and after ACTH stimulation test. Her parents were consanguineous, and she had two unaffected sisters. Her physical examination was normal, except that her height and weight were above the 97th centile for height and weight of a sex- and age-matched reference population. It was noted that she had no hyperpigmentation, despite very high ACTH levels. Her eye color was bluish-gray, and skin and hair pigmentation was similar to unaffected family members. The family noted that her hair color was red during infancy and darkened as she got older. At follow-up, after replacement with hydrocortisone and reduction of serum ACTH levels, her hair had reverted to a reddish color (Fig. 1).
Fig. 1.

The patient before (A) and after treatment (B), showing the lack of hyperpigmentation and lightening of hair color on treatment.

The patient before (A) and after treatment (B), showing the lack of hyperpigmentation and lightening of hair color on treatment.

Sequencing

Genomic DNA was extracted from whole blood samples after individuals gave informed consent. The sequences of the coding exons of MC1R and MC2R and their intron/exon junctions were determined by PCR and automated sequencing.

Results

Nucleotide sequence analysis of MC2R revealed a homozygous mutation NC_000018.9:g.13885083C>A, c.455C>A (p.T152K), a loss-of function mutation previously shown to be trafficking defective (22) (Fig. 2). The parents and one unaffected sister were heterozygous for the mutation, and her other unaffected sister was wild-type. Hyperpigmentation is a classical clinical finding in FGD; to find the reason for this patient's lack of pigmentation, we sequenced MC1R. A homozygous NC_000016.9:g.89986144C>T, c.478C>T variation (p.R160W) was detected in MC1R in the proband. Her parents and sisters were heterozygous for the change (Fig. 2). This change, SNP ID rs1805008, has been linked to a red hair phenotype (8).
Fig. 2.

Pedigree and sequencing results of MC1R and MC2R for the patient and family members. The affected proband (black symbol and arrow) was homozygous for the indicated mutations. Unaffected parents and siblings (white symbols) were all heterozygous or wild-type for the mutations. Uncharacterized individuals are represented by gray symbols. Changes c.455C>A in MC2R (upper chromatograms) and c.478C>T in MC1R (lower chromatograms) are shown. Homozygous mutant and heterozygous and homozygous wild-type nucleotides are indicated by red, blue, and black arrows, respectively. Wild-type sequences from an unrelated control are indicated in the extreme right panels.

Pedigree and sequencing results of MC1R and MC2R for the patient and family members. The affected proband (black symbol and arrow) was homozygous for the indicated mutations. Unaffected parents and siblings (white symbols) were all heterozygous or wild-type for the mutations. Uncharacterized individuals are represented by gray symbols. Changes c.455C>A in MC2R (upper chromatograms) and c.478C>T in MC1R (lower chromatograms) are shown. Homozygous mutant and heterozygous and homozygous wild-type nucleotides are indicated by red, blue, and black arrows, respectively. Wild-type sequences from an unrelated control are indicated in the extreme right panels.

Discussion

Pigmentary skin changes are one of the most important clinical features and diagnostic clues in adrenal failure for clinicians. Here, we report a case of FGD without this clinical feature due to homozygous mutations in two unrelated genes, located on different chromosomes but belonging to the same family, the melanocortin receptors. The ligands of MC2R and MC1R are ACTH and α-MSH, respectively, both products of the same gene, POMC, which encodes a polypeptide hormone precursor that undergoes tissue-specific, posttranslational processing via cleavage by prohormone convertases. ACTH and α-MSH share the first 13 amino acids, and MC1R binds both peptides with similar affinity because of this structural similarity. Therefore, increased ACTH levels lead to hyperpigmentation in adrenal failure; in our case, skin pigmentation is absent due to a loss-of-function mutation in MC1R. MC1R is a control point in the regulation of pigmentation; genetic variants are detected in over 80% of individuals with red hair and/or fair skin that tan poorly, but in fewer than 20% of individuals with brown or black hair (7). The R160W change reported in our case is one of most common changes reported in red-haired individuals (8) and reduces the cAMP response to α-MSH (23–25). Our patient had red hair when she was born, which darkened as she got older; after treatment and normalization of ACTH levels, her hair gradually lightened. There are no reports of adrenal failure without pigmentation caused by AAAS, DAX-1, or SF-1 mutation, but some nonpigmented, so-called “white Addison's” cases have been reported (10–21). All such cases have been recorded in Europeans with fair skin, which suggests that MC1R variants could be implicated; in many instances, diagnosis was unexpected or delayed because of the absence of pigmentation. In only one patient was a mechanism for the absence of hyperpigmentation proposed; it was attributed to generalized vitiligo, with a high degree of melanosome degradation in secondary lysosomes being reported in a skin biopsy (15). Here we report the first case of coexistent MC2R and MC1R homozygous mutations resulting in an unusual case of FGD1 without hyperpigmentation. The finding of a MC1R mutation may explain the absence of hyperpigmentation in this case. Additionally, MC1R variants could explain cases of white Addison's disease and might also handicap early phenotypic recognition of adrenal failure.
  23 in total

1.  Loss of function mutations of the human melanocortin 1 receptor are common and are associated with red hair.

Authors:  H B Schiöth; S R Phillips; R Rudzish; M A Birch-Machin; J E Wikberg; J L Rees
Journal:  Biochem Biophys Res Commun       Date:  1999-07-05       Impact factor: 3.575

2.  CRISIS FOLLOWING CORTICOTROPHIN IN ADDISON'S DISEASE WITHOUT PIGMENTATION.

Authors:  M F ALLISON; I S BAILEY; D C CURTIN
Journal:  Postgrad Med J       Date:  1964-01       Impact factor: 2.401

3.  EIGHTY-SIX CASES OF ADDISON'S DISEASE.

Authors:  D DUNLOP
Journal:  Br Med J       Date:  1963-10-12

4.  On a case of so-called "white" Addison's disease with Cushing-like habitus after substitution with prednisone

Authors:  A JORES; J TAMM
Journal:  Acta Endocrinol (Copenh)       Date:  1959-12

5.  [Addison's disease without increase of pigmentation (so-called white Addison's disease)].

Authors:  C HEDINGER
Journal:  Schweiz Med Wochenschr       Date:  1950-05-13

6.  White Addison's disease: what is the possible cause?

Authors:  A Kendereski; D Micić; M Sumarac; S Zorić; D Macut; M Colić; A Skaro-Milić; Z Bogdanović
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

7.  Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation.

Authors:  N Flanagan; E Healy; A Ray; S Philips; C Todd; I J Jackson; M A Birch-Machin; J L Rees
Journal:  Hum Mol Genet       Date:  2000-10-12       Impact factor: 6.150

8.  Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans.

Authors:  H Krude; H Biebermann; W Luck; R Horn; G Brabant; A Grüters
Journal:  Nat Genet       Date:  1998-06       Impact factor: 38.330

9.  Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans.

Authors:  P Valverde; E Healy; I Jackson; J L Rees; A J Thody
Journal:  Nat Genet       Date:  1995-11       Impact factor: 38.330

10.  Melanocortin 1 receptor variants in an Irish population.

Authors:  R Smith; E Healy; S Siddiqui; N Flanagan; P M Steijlen; I Rosdahl; J P Jacques; S Rogers; R Turner; I J Jackson; M A Birch-Machin; J L Rees
Journal:  J Invest Dermatol       Date:  1998-07       Impact factor: 8.551

View more
  7 in total

1.  "patients can have as many gene variants as they damn well please": why contemporary genetics presents us daily with a version of Hickam's dictum.

Authors:  Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2012-05       Impact factor: 5.958

Review 2.  POMC: The Physiological Power of Hormone Processing.

Authors:  Erika Harno; Thanuja Gali Ramamoorthy; Anthony P Coll; Anne White
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

Review 3.  MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.

Authors:  Jose C García-Borrón; Zalfa Abdel-Malek; Celia Jiménez-Cervantes
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-30       Impact factor: 4.693

Review 4.  ACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms?

Authors:  Davids Fridmanis; Ance Roga; Janis Klovins
Journal:  Front Endocrinol (Lausanne)       Date:  2017-02-06       Impact factor: 5.555

Review 5.  ACTH signalling and adrenal development: lessons from mouse models.

Authors:  Tatiana V Novoselova; Peter J King; Leonardo Guasti; Louise A Metherell; Adrian J L Clark; Li F Chan
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

6.  The melanocortin receptors and their accessory proteins.

Authors:  Shwetha Ramachandrappa; Rebecca J Gorrigan; Adrian J L Clark; Li F Chan
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-08       Impact factor: 5.555

Review 7.  An Insight into GPCR and G-Proteins as Cancer Drivers.

Authors:  Preeti Kumari Chaudhary; Soochong Kim
Journal:  Cells       Date:  2021-11-24       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.